BRCA1 and cancer: Furthermore, we treated carriers of BRCA1/2 variants of uncertain significance (VUS) as having the same risk as BRCA1/2 wild-type individuals, consistent with current guidelines that classify VUS as uninformative for cancer risk stratification and management (20).